Background: The current methods to predict recurrence and aggressive behaviour of meningiomas rely mainly on histological grading, histological subtype, proliferative index, as well as brain invasion. In many instances, histological grade alone fails to predict recurrence in the grade I and grade II meningiomas. Deletions of 1p and 14q have previously been reported to correlate with poor prognosis in terms of either recurrence or higher histological grades. The Her2neu (ErbB2) amplification has been shown to be a useful predictor of aggressive behaviour in breast and ovarian tumours, but its significance in meningioma is so far uncertain.
Method: In order to determine the cytogenetic differences between 22 recurrent and 25 non-recurrent meningiomas of all grades, we used fluorescent in situ hybridization (FISH) DNA probes for 1p36, 14q11.2 and 17q11.2-12 (Her2neu) on formalin fixed paraffin embedded (FFPE) tissue from the Brain Tumour Tissue Bank (BTTB), London Health Science Center (LHSC).
Results: We showed a positive association for meningioma recurrence correlated with 1p36 deletion plus or minus 14q 11.2 deletions in all grades of meningiomas. The Her2neu amplification was strongly associated with 1p/14q co-deletion in cases of recurrent meningiomas, especially the higher grade tumours.
Conclusion: These cytogenetic markers can be applied in addition to histological grading for predicting the risk of recurrence and biological behaviour.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/s0317167100014311 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort.
Mol Diagn Ther
November 2024
Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany.
Article Synopsis
- Salivary gland carcinomas (SGC) are diverse with 24 subtypes, primarily treated through surgery and radiotherapy, but have a low 5-year survival rate of 20% for patients with recurrence or metastasis.
- A study involving 55 SGC patients investigated various druggable molecular alterations using immunohistochemical staining and fluorescence in situ hybridization, finding a 54.4% prevalence of such alterations, with EGFR overexpression being the most common.
- Targeted therapies like trastuzumab deruxtecan and pembrolizumab may offer new treatment options for patients with RM-SGC who cannot undergo salvage surgery.
Aflatoxin exposure is associated with an increased risk of gallbladder cancer.
Int J Cancer
January 2025
Department of Gastroenterology, PGIMER, Chandigarh, India.
Gall bladder cancer (GBC) is common among the socioeconomically deprived populations of certain geographical regions. Aflatoxin is a genotoxic hepatocarcinogen, which is recognized to have a role in the pathogenesis of hepatocellular carcinoma. However, the role of aflatoxin in the pathogenesis of GBC is largely unknown.
View Article and Find Full Text PDFNarrative review on the evolving role of HER2/neu targeting in uterine serous cancers.
Ann Transl Med
August 2024
Department of Gynecological Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Background And Objective: Serous endometrial cancers (ECs) are an aggressive histotype of ECs which are disproportionately responsible for 40% of cancer-specific mortality rates despite constituting only 5-10% of all uterine cancers in incidence. In recent times, it has become increasingly evident that about 20-40% of uterine serous cancers (USCs) have molecular alterations in pathway with human epidermal growth factor receptor 2 (HER2/neu) amplification or overexpression. We summarise the evidence on genetic and molecular alterations in HER2/neu pathway in USC with a focus on testing criteria, targeting agents and resistance mechanisms.
View Article and Find Full Text PDFHER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study.
Asian Pac J Cancer Prev
June 2024
Department of Pathology, Faculty of Medicine, Assiut University Hospital, Assiut, Egypt.
Background: Colorectal cancer (CRC) is a major public health problem and one of leading cancer related death all over the world. One of the prognostic parameters that play a role in different types of cancer is HER2. However, the role of HER2 in CRC and its relation with clinicopathological features and survival is conflicting.
View Article and Find Full Text PDFHer-2/neu gene amplification and its correlation with other prognostic factors in Iranian breast cancer patients.
Mol Biol Rep
June 2024
Department of Molecular Medicine, Faculty of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Background: Breast cancer is one of the most common diseases in females, arising from overexpression of a variety of oncogenes like HER2/neu. The amplification rate of this gene is variable in different breast cancer patients. In this study, the amplification of the HER2/neu oncogene was distinguished in breast cancer patients and its correlation with prognostic factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!